Influence of rosuvastatin combined with noninvasive positive pressure ventilation on pulmonary ventilation function, SGRQ score and laboratory parameters of patients with AECOPD

Abstract

Objective To investigate the influence of rosuvastatin combined with noninvasive positive pressure ventilation on pulmonary ventilation function, SGRQ score and laboratory parameters of patients with AECOPD. Methods 110 patients with AECOPD were chosen and they were randomly divided into two groups according to the digital table, each group in 55cases.The control group received noninvasive positive pressure ventilation, and the observation group received rosuvastatin on the basis of the control group.The number of acute exacerbation and re-hospitalization, pulmonary ventilation function, SGRQ score, 6MWT, the levels of IL-8, CRP, alanine aminotransferase, triacylglycerol and total cholesterol before and after treatment of the two groups were compared. Results The number of acute exacerbation and re-hospitalization of the observation group were significantly lower than those of the control group(t=3.19, 2.84, all P<0.05). The levels of FEV1 and FEV1/FVC after treatment of both two groups were significantly higher than before treatment(t=2.88, 3.14, 2.90, 3.42, all P<0.05). The levels of FEV1 and FEV1/ FVC after treatment of the observation group were significantly higher than those of the control group(t=2.38, 2.61, all P<0.05). The SGRQ scores and 6MWT after treatment of both two groups were significantly better than those before treatment(t=2.59, 2.51, 2.84, 3.17, all P<0.05). The SGRQ scores and 6MWT after treatment of observation group were significantly better than those of the control group (t=2.59, 2.51, all P<0.05). The levels of the IL-8, CRP, alanine aminotransferase, triacylglycerol and total cholesterol after treatment of both two groups were significantly lower than those before treatment (t=2.78, 2.50, 2.94, 3.07, 4.26, 3.89, 3.02.3.67, all P<0.05). The levels of IL-8, CRP, alanine aminotransferase, triacylglycerol and total cholesterol after treatment of the observation group were significantly lower than those of the control group(t=2.64, 2.33, 2.81, 3.15, all P<0.05). Conclusion Rosuvastatin combined with noninvasive positive pressure ventilation in the treatment of patients with AECOPD can efficiently promote lung function recovery, higher quality of life and exercise endurance, improve the laboratory indicators and is help to avoid the acute attack and re-hospitalization for long-term. Key words: Pulmonary disease, chronic obstructive; Intermittent positive-pressure ventilation; Rosuvastatin